Patricia Inacio, PhD,  science writer—

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inacio

Alzheimer’s Disease Cooperative Study, Biohaven Jointly Launch Clinical Trial for Trigriluzole

Biohaven and the Alzheimer’s Disease Cooperative Study (ADCS) have jointly launched a Phase 2 clinical trial for the investigational drug trigriluzole, a glutamate modulating candidate that could potentially improve symptoms in patients with mild to moderate Alzheimer’s disease. Preclinical studies and post-mortem human Alzheimer’s studies suggest that abnormalities in the…

Link Between Lysosomes and Granulins in Brain Cells May Aid Understanding of Alzheimer’s

Researchers developed antibodies targeting a group of proteins called granulins, and discovered for the first time that they’re important to the well-being of lysosomes, which are vital organelles linked to neurodegenerative diseases that include Alzheimer’s disease (AD) and frontotemporal dementia (FTD). This discovery, by a research team at Emory University School of…

Biomarkers May Help Develop Better and More Personalized Alzheimer’s Treatments, Study Suggests

The physical properties of proteins in the spinal fluid and blood of people with Alzheimer’s disease may constitute valuable biomarkers to help diagnose disease progression and predict patients’ outcomes, new research from The Ohio State University suggests. The biomarkers may help researchers develop better treatments in the future, especially for later stages of…

New Method Promises to Quickly Identify Abnormal Proteins Involved in Alzheimer’s

Researchers developed a new method for capturing proteins implicated in several diseases, including Alzheimer’s. The technique promises to accelerate the identification of altered proteins underlying disease progression (biomarkers). This knowledge may later translate into new targeted therapeutics. The study, “A mutant O-GlcNAcase enriches Drosophila developmental regulators,” was published in the…

Preventing Diabetes May Help Halt Alzheimer’s Progression in New York State, Report Says

The state of New York lacks effective measures for preventing diabetes, which is fueling a dramatic increase in Alzheimer’s disease. So says a new document, “Unprevented Diabetes Means Unnecessary Alzheimer’s,” issued by Health People: Community Preventive Health Institute. Doctors say diabetes increases the risk of getting Alzheimer’s by 40 percent. Currently, New York state…

ALZ-801 Works Against Alzheimer’s by Preventing Protein Component Clumping, Study Reports

The Alzheimer’s therapy ALZ-801 works by preventing protein components from clumping together to trigger the amyloid plaque accumulation in the brain that causes the disease, researchers say. Disease-modifying drugs for Alzheimer’s and other neurodegenerative diseases could evolve from the findings, the team said. Researchers knew that tramiprosate, the active ingredient in …